Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NameCOBAS TAQMAN HBV TEST
Classification Namehepatitis viral b dna detection
Generic Namecobastaqman hbv test for use with the high pure system
ApplicantROCHE MOLECULAR SYSTEMS, INC.
PMA NumberP050028
Date Received08/02/2005
Decision Date09/04/2008
Product Code
MKT[ Registered Establishments with MKT ]
Docket Number 08M-0501
Notice Date 09/11/2008
Advisory Committee Microbiology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for cobas taqman hbv test for use with the high pure system. This device is indicated for: the cobas taqman hbv test for use with the high pure system is an in vitro nucleic acid amplification test for the quantitation of hepatitis b virus (hbv) dna in human serum or plasma (edta), using the high pure viral nucleic acid kit for manual specimen preparation and the cobas taqman 48 analyzer for automated amplification and detection. The test is intended for use as an aid in the management of patients with chronic hbv infection undergoing anti-viral therapy. The assay can be used to measure hbv dna levels at baseline and during treatment to aid in assessing response to treatment. The results from the cobas taqman hbv test must be interpreted within the context of all relevant clinical and laboratory findings. Assay performance characteristics have been established for individuals treated with adefovir dipivoxil. Assay performance for determining the state of hbv infection has not been established. The cobas taqman hbv test is not intended for use as a screening test for blood or blood products for the presence of hbv or as a diagnostic test to confirm the presence of hbv infection.
Approval Order Approval Order
Supplements: S001 S002 S003 S004 S005 S006 
S007 S008 S011 S012 S013 S015 
S016 S017 S019 S020 S021 S022 
S023 S024 S025 S026 S027 S028 
S029 S030 S031 S032 
-
-